促皮质素(Corticotropin) - 药物靶点：melanocortin receptor_在研适应症：强直性脊柱炎，银屑病关节炎，脉络膜炎_专利_临床

概要

基本信息

药物类型

合成多肽

别名

ACTH、Adrenocorticotrophin、Adrenocorticotropic hormone

+ [10]

靶点

melanocortin receptor

作用方式

激动剂

作用机制

melanocortin receptor激动剂(黑皮质素受体激动剂)

治疗领域

免疫系统疾病感染神经系统疾病+ [5]

在研适应症

强直性脊柱炎银屑病关节炎脉络膜炎+ [18]

非在研适应症

肌萎缩侧索硬化糖尿病肾病免疫球蛋白a肾病+ [6]

原研机构

Sanofi-Aventis U.S. LLC

在研机构

Mallinckrodt Plc

Questcor Pharmaceuticals, Inc.

非在研机构

Sanofi-Aventis U.S. LLCMallinckrodt Pharmaceuticals Ireland Ltd.

ANI Pharmaceuticals, Inc.

权益机构-

最高研发阶段批准上市

首次获批日期

美国 (1950-07-03),

银屑病关节炎皮肌炎水肿+ [10]

最高研发阶段(中国)-

特殊审评-

登录后查看时间轴

结构/序列

Sequence Code 975147

来源: *****

关联

83

项与促皮质素相关的临床试验

NCT06964269

/ Recruiting临床4期

A Phase 4 Pilot Study With Extension to Assess the Use of Acthar Gel Single-Dose Pre-Filled SelfJectTM Injector in Patients With Moderate-Severe Keratitis and Autoimmune Disease and the Effect on Corneal Nerves and Neuropathic Corneal Pain

Single-site, open label pilot study of 20 autoimmune patients diagnosed with dry eye demonstrating via the proparacaine challenge some peripheral corneal pain component. At least 16 patients will receive and complete 12 weeks of 80 units of Acthar Gel to be injected subcutaneously twice weekly via Acthar Gel single-dose pre-filled SelfJectTM injector (SelfJect) to assess the effects on subjective sensation of ocular pain, conjunctival and corneal staining, in vivo assessments of corneal nerves as measured by confocal imaging, VAS scales of common neuropathic pain symptoms and comfort of SelfJect will be assessed.

开始日期2025-02-11

申办/合作机构

Toyos Clinic

ChiCTR2400090753

/ SuspendedN/AIIT

Diagnostic Value of ACTH Stimulation Test under 1mg dexamethasone suppression test in differentiating the Subtypes of Primary Aldosteronism

开始日期2024-10-15

申办/合作机构-

CTRI/2024/06/069346

/ Not yet recruiting临床4期IIT

A comparison of Porcine Sequence Corticotropin to Tetracosactide Hexaacetate on stimulated 17 Hydroxyprogesterone levels in healthy individuals. - NIL

开始日期2024-07-01

申办/合作机构-

100 项与促皮质素相关的临床结果

登录后查看更多信息

100 项与促皮质素相关的转化医学

登录后查看更多信息

100 项与促皮质素相关的专利（医药）

登录后查看更多信息

6,484

项与促皮质素相关的文献（医药）

2025-08-01·BRAIN & DEVELOPMENT

Endocrinological study of low-dose adrenocorticotropic hormone therapy without tapering in infantile epileptic spasms syndrome

Article

作者: Yamauchi, Taisuke ; Suzuki, Tomonori ; Morita, Shumpei ; Kashimada, Kenichi ; Tamura, Yumie ; Takasawa, Kei ; Nomura, Toshihiro ; Takahashi, Koji ; Shiraku, Hiroshi ; Mizuno, Tomoko

BACKGROUND:

Adrenocorticotropic hormone (ACTH) therapy is effective for infantile epileptic spasms syndrome (IESS) and other types of refractory epilepsy; however, concerns remain regarding the risk of potential adrenal insufficiency, particularly when ACTH therapy is discontinued without dose tapering. Studies on comprehensive endocrinological evaluation of adrenocortical function following low-dose ACTH therapy without tapering are limited.

METHODS:

We collected the data of patients who were diagnosed with IESS and received ACTH therapy using synthetic ACTH at 0.005-0.0125 mg/kg/day (equivalent to natural ACTH at 0.2-0.5 IU/kg/day) for 14 days without tapering, and underwent an ACTH stimulation test following ACTH therapy completion for adrenocortical function evaluation. Moreover, body weight, blood pressure, and electrolytes were measured before and after treatment.

RESULTS:

A total of 11 patients, aged between 3 months and 1 year and 6 months, were enrolled. ACTH therapy was effective in all 11 patients. During the observation period, 3 patients developed seizure recurrence; however, none of the patients exhibited symptoms of adrenal insufficiency. The ACTH stimulation test confirmed normal adrenocortical function in all cases, with peak cortisol levels exceeding 20 μg/dL. After treatment, a significant increase in body weight and blood pressure were observed.

CONCLUSION:

Low-dose ACTH therapy without tapering can be endocrinologically safe. The result provides useful information for reducing hospitalization duration and minimizing side effects. To validate these findings, further studies with larger cohorts are needed.

2025-08-01·PEDIATRIC NEUROLOGY

Safety, Efficacy, and Tolerability of Ketogenic Diet Versus Adrenocorticotropic Hormone in Infantile Epileptic Spasms Syndrome: A Randomized Controlled Trial

Article

作者: Kamila, Gautam ; Sondhi, Vishal ; Mahesan, Aakash ; Pandey, Ravindra Mohan ; Chakrabarty, Biswaroop ; Jauhari, Prashant ; Gulati, Sheffali ; Gupta, Kanak Lata ; Agarwala, Anuja

BACKGROUND:

Ketogenic diet (KD) is efficacious in adrenocorticotrophic hormone (ACTH)-refractory infantile epileptic spasms syndrome (IESS) with lesser side effects. Upfront treatment with KD in IESS is least explored. This study aims to compare the efficacy of upfront treatment with KD compared with ACTH in IESS.

METHODS:

In this open-label randomized controlled trial, infants aged 6-24 months with an electroclinical diagnosis of IESS were enrolled and randomly assigned to either the KD or the ACTH arm. The primary efficacy end point was to compare spasm reduction at six weeks of therapy from the baseline between the two arms. Secondary end points were electroclinical spasm cessation rates at six weeks, relapse after initial clinical response, adverse effects, and developmental progress at 24 weeks of follow-up.

RESULTS:

A total of 178 children were screened; 87 children were randomized of which 41 received ACTH and 42 received KD. At six weeks of therapy, the median (interquartile range) percentage spasm reduction was comparable (66.7% [24.5-100] for ACTH vs 76.6% [56.3-100] for KD [P = 0.39]). The electroclinical spasm cessation rates were similar. There were higher relapses in the ACTH arm in those with initial clinical spasm cessation (38.9% ACTH vs 0 KD, P = 0.004) at 24 weeks' follow-up. The proportion of children having at least one side effect was higher in the ACTH arm (95.1% ACTH vs 59.5% KD; relative risk, 1.6 [1.23-2.1]).

CONCLUSIONS:

KD may not be inferior to ACTH as first-line therapy for IESS with a better side effect profile and fewer relapses compared with ACTH.

2025-06-01·Neurology and Therapy

Factors Influencing the Response of Patients with Infantile Epileptic Spasms Syndrome to ACTH as Repeated First-Line Therapy

Article

作者: Pang, Ping ; Zhang, Ziyan ; Wan, Lin ; Ge, Wenrong ; Yang, Guang

INTRODUCTION:

The treatment of infantile epileptic spasms syndrome (IESS) aims to achieve spasm control. Current first-line interventions include hormone therapy (adrenocorticotropic hormone [ACTH] and corticosteroids) and vigabatrin. Despite treatment, the response rate remains at around 40%, with some infants experiencing relapse after achieving initial spasm control. In certain cases, a second course of first-line therapy may be warranted. The objective of this study was to perform a secondary analysis of data from our previously published studies to elucidate factors influencing the efficacy of ACTH following its re-administration after the lack of response to the initial first-line treatment or relapse.

METHODS:

We conducted a retrospective analysis of clinical data from children with IESS who had experienced treatment failure or relapse following initial first-line therapy and who subsequently received ACTH at our institution as a second first-line treatment. We examined such variables as etiological classification, interval between treatments, age at first epileptic seizure, radiological findings, and changes in pharmacological treatment modalities, with the overall aim to assess the impact of these variables on the short-term response (disappearance of spasms for > 4 weeks and without hypsarrhythmia pattern) to the second administration of the first-line therapy.

RESULTS:

Among the 128 patients with IESS identified and included in the analysis, 50 (39.1%) achieved a short-term response. Comparative analysis indicated that responders had a shorter duration between the initial first-line therapy and the initiation of the second first-line treatment (median 1.00 [interquartile range {IQR} 0.00, 2.00] vs. 1.75 [IQR 0.50, 3.88] months), were younger at the time of the second first-line treatment (median 11 [IQR 8, 17] vs. 16 [IQR 10, 24] months, p = 0.008), and were less likely to present with additional seizure types during spasm episodes (12.0% vs. 28.2%, p = 0.030). A multifactorial regression model indicated that older age at first seizure and a short-term response to initial first-line treatment were associated with a higher likelihood of obtaining an initial response in the subsequent ACTH treatment (odds ratio [OR] 2.69, 95% confidence interval [CI] 1.39, 7.23, p = 0.014 and OR 5.41, 95% CI 1.48, 23.90, p = 0.016, respectively). Conversely, an older age at the time of the initial first-line treatment, an older age at the onset of epileptic spasms, and patients with congenital structural abnormalities without genetic abnormalities were less likely to achieve an initial response in subsequent ACTH treatment (OR 0.85, 95% CI 0.78, 0.92, p < 0.001; OR 0.43, 95% CI 0.16, 0.82, p = 0.032; and OR 0.18, 95% CI 0.04, 0.69, p = 0.016, respectively)..

CONCLUSION:

A second ACTH therapy regimen (second first-line treatment) may help some children with IESS who did not respond to the initial treatment or who subsequently relapsed, with one-third of patients responding in the short-term. Congenital anomalies without genetic abnormalities and older spasm onset age lessen the odds of response, while younger age at ACTH re-treatment could improve these. ACTH may be reconsidered after initial treatment response followed by relapse.

78

项与促皮质素相关的新闻（医药）

2025-07-07

·药明康德

疾病控制率达100%的免疫联合疗法；6个月无进展生存率近70%的靶向组合疗法…… | 一周盘点

▎药明康德本期看点1. 天境生物（I-Mab）公布了其双特异性抗体givastomig联合nivolumab和mFOLFOX6，一线治疗Claudin 18.2阳性晚期转移性胃癌患者的1b期试验的积极数据，在所有剂量组中确认的客观缓解率（ORR）为71%，疾病控制率（DCR）达100%。2. 多靶点抑制剂gedatolisib联合雄激素受体抑制剂治疗转移性去势抵抗性前列腺癌（mCRPC）的早期临床结果积极，6个月的放射学无进展生存率（rPFS）达66%。Givastomig：公布1b期联合治疗试验数据天境生物公布了其双特异性抗体givastomig的1b期联合治疗试验的积极数据。Givastomig是一种靶向Claudin 18.2（CLDN18.2）阳性肿瘤细胞的双特异性抗体，在表达Claudin 18.2的肿瘤微环境中通过4-1BB信号通路有条件地激活T细胞。该药由天境生物牵头与ABL Bio公司共同开发，两方平等共享除大中华区和韩国以外的全球权益。目前，givastomig正被开发用于一线治疗转移性胃癌，并具有在其他实体瘤中进一步拓展的潜力。截至2025年5月15日的数据，17例Claudin 18.2阳性晚期转移性胃癌患者接受了不同剂量的givastomig联合nivolumab和mFOLFOX6作为一线治疗。数据显示，在所有剂量组中确认的ORR为71%（12/17），DCR达100%。在选定用于剂量扩展的两个剂量组（8 mg/kg和12 mg/kg）中，ORR为83%（10/12）。值得注意的是，即使在PD-L1或CLDN18.2表达水平较低的患者中也观察到了缓解。17名患者中有8名仍在接受治疗，截至数据截止日期，最长的治疗持续时间为13.3个月。安全性方面，联合疗法的耐受性良好，未出现3级或以上的恶心呕吐事件，仅有一例3级治疗相关不良事件（肝酶升高）。Gedatolisib：公布1期联合治疗试验数据Celcuity公司公布了其在研药物gedatolisib在一项针对转移性去势抵抗性前列腺癌患者的1期临床试验中的初步积极数据。Gedatolisib是一种强效的多靶点抑制剂，可同时靶向所有四种I类PI3K亚型以及mTOR复合物mTORC1和mTORC2，从而全面阻断关键的PI3K/AKT/mTOR（PAM）信号通路。该试验评估了gedatolisib联合雄激素受体抑制剂darolutamide在mCRPC患者中的安全性和初步疗效。截至2025年5月30日的数据，6个月的rPFS为66%。安全性方面，没有患者因治疗相关不良事件停止治疗，也未发生剂量调整，没有3级高血糖事件，仅10.5%的患者出现2-3级口腔炎，均为可控范围。在另一项gedatolisib联合曲妥珠单抗作为3线疗法治疗HER2阳性转移性乳腺癌患者的2期临床试验中，ORR为43%。ART26.12：公布首个人体试验数据Artelo Biosciences公司公布了其在研药物ART26.12的首个人体临床试验的积极结果。ART26.12是一种新型脂肪酸结合蛋白5（FABP5）抑制剂。作为一种外周作用的非阿片类、非甾体类镇痛剂，其初步临床开发目标是用于治疗化疗引起的周围神经病变（CIPN）。新闻稿指出，ART26.12是首个在人体中进行评估的口服活性FABP5抑制剂。此次公布的数据显示，ART26.12在健康受试者中表现出良好的安全性和可预测的药代动力学特性，与其此前在临床前研究中观察到的表现一致。Aritinercept（AUR200）：公布1期临床试验数据Aurinia Pharmaceuticals公司公布了其用于治疗自身免疫疾病的B细胞活化因子（BAFF）和增殖诱导配体（APRIL）双重抑制剂aritinercept的1期单剂量递增（SAD）研究的积极结果。Aritinercept在所有测试的剂量水平下都具有良好的耐受性。单剂量aritinercept可使受试者的免疫球蛋白稳定且持久地减少，从基线到接受治疗后第28天，免疫球蛋白A（IgA）、免疫球蛋白M（IgM）和免疫球蛋白G（IgG）的平均降幅分别为48%、55%和20%。药效学效应支持每月一次的给药方案。参考资料（可上下滑动查看）[1] Iksuda Therapeutics receives FDA IND clearance for IKS014. Retrieved July 1, 2025, from https://www.iksuda.com/news-views/iksuda-therapeutics-receives-fda-ind-clearance-for-iks014/[2] Aurinia Announces Positive Results from Phase 1 Study of Aritinercept (AUR200). Retrieved July 1, 2025, from https://pipelinereview.com/aurinia-announces-positive-results-from-phase-1-study-of-aritinercept-aur200/[3] Rocket Pharmaceuticals Announces FDA IND Clearance of RP-A701 for the Treatment of BAG3-associated Dilated Cardiomyopathy. Retrieved July 1, 2025, from https://ir.rocketpharma.com/news-releases/news-release-details/rocket-pharmaceuticals-announces-fda-ind-clearance-rp-a701[4] UK MHRA Approval Received for First-In-Human Trial of Rincell-1, a First-In-Class Regenerative Cell Therapy for Sensorineural Hearing Loss. Retrieved July 1, 2025, from https://www.globenewswire.com/news-release/2025/07/01/3108053/0/en/UK-MHRA-Approval-Received-for-First-In-Human-Trial-of-Rincell-1-a-First-In-Class-Regenerative-Cell-Therapy-for-Sensorineural-Hearing-Loss.html[5] Sensorion Announces Preliminary Positive Data from the First Cohort of the Audiogene Phase 1/2 Gene Therapy Clinical Trial. Retrieved July 1, 2025, from https://pipelinereview.com/sensorion-announces-preliminary-positive-data-from-the-first-cohort-of-the-audiogene-phase-1-2-gene-therapy-clinical-trial/[6] Celcuity Reports Clinical Data from Two Early Phase Studies of Gedatolisib. Retrieved July 1, 2025, from https://www.globenewswire.com/news-release/2025/06/30/3107366/0/en/Celcuity-Reports-Clinical-Data-from-Two-Early-Phase-Studies-of-Gedatolisib.html[7] PRD Therapeutics Announces Initiation of First-in-Human Study for PRD001. Retrieved July 1, 2025, from https://prdtherapeutics.com/en/news015/[8] Neurocrine Biosciences Announces Initiation of Phase 1 Clinical Study Evaluating NBIP-01435, a Long-Acting Corticotropin-Releasing Factor Type 1 Receptor Antagonist. Retrieved July 1, 2025, from https://www.prnewswire.com/news-releases/neurocrine-biosciences-announces-initiation-of-phase-1-clinical-study-evaluating-nbip-01435-a-long-acting-corticotropin-releasing-factor-type-1-receptor-antagonist-302494787.html[9] Artelo Biosciences Announces Positive First-in-Human Data for ART26.12, a Novel Non-Opioid Treatment Candidate for Persistent Pain. Retrieved July 1, 2025, from https://ir.artelobio.com/news-events/press-releases/detail/152/artelo-biosciences-announces-positive-first-in-human-data[10] Instil Bio Announces U.S. F.D.A. Clearance of Investigational New Drug (IND) Application for AXN-2510, a PD-L1xVEGF Bispecific Antibody, for a Phase 1 Trial in Relapsed/Refractory Solid Tumors. Retrieved July 1, 2025, from https://www.globenewswire.com/news-release/2025/07/02/3109003/0/en/Instil-Bio-Announces-U-S-F-D-A-Clearance-of-Investigational-New-Drug-IND-Application-for-AXN-2510-a-PD-L1xVEGF-Bispecific-Antibody-for-a-Phase-1-Trial-in-Relapsed-Refractory-Solid-.html[11] I-Mab Presents Positive Givastomig Phase 1b Dose Escalation Data in Combination with Immunochemotherapy in Patients with 1L Gastric Cancers at ESMO GI 2025. Retrieved July 1, 2025, from https://www.globenewswire.com/news-release/2025/07/02/3109334/0/en/I-Mab-Presents-Positive-Givastomig-Phase-1b-Dose-Escalation-Data-in-Combination-with-Immunochemotherapy-in-Patients-with-1L-Gastric-Cancers-at-ESMO-GI-2025.html免责声明：本文仅作信息交流之目的，文中观点不代表药明康德立场，亦不代表药明康德支持或反对文中观点。本文也不是治疗方案推荐。如需获得治疗方案指导，请前往正规医院就诊。版权说明：欢迎个人转发至朋友圈，谢绝媒体或机构未经授权以任何形式转载至其他平台。转载授权请在「药明康德」微信公众号回复“转载”，获取转载须知。分享，点赞，在看，聚焦全球生物医药健康创新

免疫疗法临床结果临床2期

2025-07-04

·梅斯医学

26岁小伙婚后久备不孕，一查竟“无精”！医生揭开真相：是从小藏在体内的“激素缺陷”作祟！

26岁的小周，外表阳刚、身体健壮，婚后与妻子备孕两年却始终没传来好消息。起初两人以为是“压力大”“时机不对”，直到亲戚提醒去查查“男方问题”，小周才忐忑地去了医院。可当“无精症”三个字出现在检查报告上时，小周彻底懵了。怎么可能？他从小身体不错，声音粗、长得快，还比同龄男孩早长胡子，怎么会无精呢？带着疑问，小周被转诊至内分泌科。在医生的追问下，他回忆起自己一直存在的一些“奇怪情况”——成年后身高早早停止增长，体毛比常人多，脸上总爱长痘，情绪起伏也很大。医生敏锐地意识到这并不寻常，随即完善了性激素、肾上腺功能及基因检测。背后竟是因为基因突变通过全面的检查与基因分析，医生终于揭开了小周多年健康问题的真相——21羟化酶缺乏症（21-OHD）。基因检测显示，小周携带CYP21A2基因第2号内含子的I2g纯合突变。这一基因突变导致肾上腺皮质功能异常，使21羟化酶活性丧失，从而引发一系列激素紊乱。长期高水平的雄激素（雄烯二酮和硫酸去氢表雄酮）反馈抑制了垂体促性腺激素（LH、FSH）的分泌，造成了无精症和性腺发育异常。此外，MRI影像检查还提示双侧肾上腺增生，进一步印证了这一诊断。女性多发21-OHD 是先天性肾上腺增生症中最常见的一类，约占先天性肾上腺增生症的95%，主要是由于CYP21 的缺乏导致肾上腺糖皮质激素和(或)肾上腺盐皮质激素合成障碍而反馈性引起ACTH分泌增加，从而导致肾上腺增生、肾上腺来源的雄激素增多。21-OHD根据临床表现和激素水平可分为经典型(失盐型和单纯男性化型)和非经典型。21-OHD是常染色体隐性遗传疾病，但女性发病率明显高于男性。临床表现21羟化酶缺乏症（21-OHD）的临床表现因CYP21基因变异导致的酶活性下降程度不同而有所差异，主要分为以下三种类型：1.失盐型（酶活性完全缺失）：新生儿期即表现为肾上腺危象，如低钠血症、高钾血症和低血压，严重者危及生命。2.单纯男性化型（酶活性保留1%~2%）：可合成少量醛固酮，避免新生儿肾上腺危象，但由于雄激素过高，患者可表现为性早熟，骨龄超前，成年后身高明显低于同龄人。3.非经典型（酶活性保留20%~60%）：男性患者：临床症状较隐匿，性功能通常不受影响，但雄激素过高可能导致不育，常因成年后不育就诊。常见原因包括睾丸肾上腺残余瘤（TARTs）和促性腺激素分泌被反馈抑制，导致睾丸功能受损及生精障碍。女性患者：青春期可能表现为月经紊乱（如闭经、月经稀发）和不孕，较男性患者更容易被发现和确诊。治疗21-OHD 的治疗目标是通过补充糖皮质激素抑制促肾上腺皮质激素（ACTH）的分泌，从而减少肾上腺分泌过多的雄激素，恢复正常的促性腺激素分泌水平，以改善男性患者的生精功能和女性患者的排卵功能。对于非经典型21-OHD患者，糖皮质激素替代治疗是主要的治疗手段，常用药物包括强的松（每日 5.0～7.5 mg，分 1～2 次口服）、强的松龙（每日 3～7 mg，分 1～2 次口服）或地塞米松（每日 0.25～0.50 mg 口服）。治疗过程中需定期监测患者的性激素水平，随时调整糖皮质激素的剂量以优化疗效并尽量减少副作用。早期干预和长期随访是治疗的关键。通过及时补充糖皮质激素，不仅可以改善患者的生精功能，还能有效提高生育能力。总之，治疗应以个体化为原则，根据患者病情的变化调整治疗方案，同时加强长期随访和管理。参考资料：[1]Auer MK, Nordenström A, Lajic S, Reisch N. Congenital adrenal hyperplasia. Lancet. 2023;401(10372):227-244. doi:10.1016/S0140-6736(22)01330-7[2] 李亚玲,袁刚,谢君辉.男性21羟化酶缺乏症一例[J].临床内科杂志,2022,39(08):564-565.来源 | 梅斯医学编辑 | wanny神经系统罕见病交流群↓点击下方“阅读原文”，下载梅斯医学APP吧！

临床研究临床结果

2025-06-18

·GlobeNewswire-Health Care

ANI Pharmaceuticals Announces Presentation of New Preclinical Data

June 12, 2025 -- ANI Pharmaceuticals, Inc. (ANI or the Company) (Nasdaq: ANIP) today announced new preclinical data on the use of Purified Cortrophin Gel (repository corticotropin injection USP) (Cortrophin Gel) in a mouse model of murine collagen-induced inflammatory arthritis. “In a preclinical model of murine collagen-induced arthritis, repository corticotrophin injection attenuated joint swelling in mice, and decreased inflammatory cytokine response without causing additional bone turnover, as compared to controls,” said Mary Pao, MD, PhD, Chief Medical Officer of Rare Disease at ANI. “These data further expand our understanding of Cortrophin Gel’s mechanism of action.” The effect of repository corticotropin injection (RCI, an equivalent to Cortrophin Gel in this model), when used as monotherapy, was evaluated using a mouse collagen-induced arthritis (CIA) model to assess the inflammatory response and bone damage. Following CIA induction, mice received subcutaneous RCI (40 or 400 U/kg twice daily), or vehicle control. RCI treatment had a significant dose dependent effect on attenuating CIA-induced joint swelling and clinical scores at both doses when compared to vehicle with the greatest effect at the 400 U/kg dose. Additionally, RCI treatment at the 400 U/kg dose resulted in a reduction in inflammatory cytokine response, but no disruption in immunoglobulin G formation and no additive bone loss. This research was led by Maripat Corr, MD, Professor of Medicine at the University of California San Diego, La Jolla, CA and Nancy Lane, MD, Distinguished Professor of Medicine and Rheumatology at the University of California Sacramento, Davis, CA. “The data for Cortrophin Gel presented at EULAR is part of a broader program demonstrating ANI’s commitment to scientific and clinical research for our products. We are proud to collaborate with leading scientists and clinicians on studies designed to better understand our products, in the hopes of helping patients,” said Nikhil Lalwani, President and Chief Executive Officer at ANI. The data was presented in a poster session at the European Alliance of Associations for Rheumatology (EULAR) 2025 Congress being held June 11-14, 2025, in Barcelona, Spain. Presentation Title: Repository corticotropin injection (RCI) attenuates inflammatory response in a pre-clinical murine collagen-induced arthritis model Session Title: Poster Tour II; Basic Poster Tours: New Molecules on the Horizon in Spondylarthritis and Psoriatic Arthritis Presentation #: POS0014 Presentation Time: Wednesday, 11 June: 15:54-16:00 CEST Lead Author: Maripat Corr, MD ANI Pharmaceuticals, Inc. (Nasdaq: ANIP) is a diversified biopharmaceutical company committed to its mission of “Serving Patients, Improving Lives" by developing, manufacturing, and commercializing innovative and high-quality therapeutics. The Company is focused on delivering sustainable growth through its Rare Disease business, which markets novel products in the areas of ophthalmology, rheumatology, nephrology, neurology, and pulmonology; its Generics business, which leverages R&D expertise, operational excellence, and U.S.-based manufacturing; and its Brands business. The content above comes from the network. if any infringement, please contact us to modify.

上市批准

100 项与促皮质素相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
D00146	促皮质素	H01AA01	DB01285

研发状态

批准上市

10 条最早获批的记录,

登录

后查看更多信息

适应症	国家/地区	公司	日期
膜性肾小球肾炎	加拿大	Mallinckrodt Plc	2014-12-23
脉络膜炎	美国	Questcor Pharmaceuticals, Inc.	2010-10-15
虹膜睫状体炎	美国	Questcor Pharmaceuticals, Inc.	2010-10-15
虹膜炎	美国	Questcor Pharmaceuticals, Inc.	2010-10-15
角膜炎	美国	Questcor Pharmaceuticals, Inc.	2010-10-15
视神经炎	美国	Questcor Pharmaceuticals, Inc.	2010-10-15
后葡萄膜炎	美国	Questcor Pharmaceuticals, Inc.	2010-10-15
强直性脊柱炎	美国	Mallinckrodt Pharmaceuticals Ireland Ltd.	1952-04-29
银屑病关节炎	美国	Sanofi-Aventis U.S. LLC	1950-07-03
皮肌炎	美国	Sanofi-Aventis U.S. LLC	1950-07-03
水肿	美国	Sanofi-Aventis U.S. LLC	1950-07-03
多形红斑	美国	Sanofi-Aventis U.S. LLC	1950-07-03
眼部疾病	美国	Sanofi-Aventis U.S. LLC	1950-07-03
幼年特发性关节炎	美国	Sanofi-Aventis U.S. LLC	1950-07-03
多发性硬化症	美国	Sanofi-Aventis U.S. LLC	1950-07-03
类风湿关节炎	美国	Sanofi-Aventis U.S. LLC	1950-07-03
结节病	美国	Sanofi-Aventis U.S. LLC	1950-07-03
血清病	美国	Sanofi-Aventis U.S. LLC	1950-07-03
婴儿痉挛	美国	Sanofi-Aventis U.S. LLC	1950-07-03
Stevens-Johnson综合征	美国	Sanofi-Aventis U.S. LLC	1950-07-03

未上市

10 条进展最快的记录,

登录

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
肌萎缩侧索硬化	临床3期	美国	Mallinckrodt Plc	2017-06-22
肌萎缩侧索硬化	临床3期	阿根廷	Mallinckrodt Plc	2017-06-22
肌萎缩侧索硬化	临床3期	加拿大	Mallinckrodt Plc	2017-06-22
肌萎缩侧索硬化	临床3期	智利	Mallinckrodt Plc	2017-06-22
肌萎缩侧索硬化	临床3期	哥伦比亚	Mallinckrodt Plc	2017-06-22
肌萎缩侧索硬化	临床3期	墨西哥	Mallinckrodt Plc	2017-06-22
肌萎缩侧索硬化	临床3期	秘鲁	Mallinckrodt Plc	2017-06-22
免疫球蛋白a肾病	临床3期	美国	Mallinckrodt Plc	2015-03-01
蛋白尿	临床3期	美国	Mallinckrodt Plc	2015-03-01
巩膜炎	临床2期	美国	Mallinckrodt Plc	2019-01-01

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT02226341 (ACTHar, CTgov)	临床4期	狼疮性肾炎	8	ACTHar Gel+CellCept (CellCept Daily & ACTHar Gel BIW (Two Times Per Week))	夢鹹積網糧顧齋繭艱膚 = 繭鹽獵糧鏇壓構簾鹽鏇醖顧鏇積遞製遞構鑰願 (襯範鑰鬱願願築顧製範, 餘齋蓋艱糧蓋齋壓壓憲 ~ 願構範憲鏇糧鏇餘構鏇) 更多	-	2025-03-07
NCT02226341 (ACTHar, CTgov)	临床4期	狼疮性肾炎	8	ACTHar Gel+CellCept (CellCept Daily & ACTHar Gel TIW (Three Times Per Week))	夢鹹積網糧顧齋繭艱膚 = 顧鹽蓋艱鏇艱遞製鏇築醖顧鏇積遞製遞構鑰願 (襯範鑰鬱願願築顧製範, 觸觸夢蓋鬱齋襯艱艱廠 ~ 衊淵網夢築構壓積構齋) 更多	-	2025-03-07
ENDO2024	N/A	转移性宫颈癌 Ki-67 \| vimentin \| CEA ... 更多	-	Chemotherapy and radiotherapy	積淵窪觸範積觸簾獵壓(網襯鹹醖衊積鹹選憲鬱) = 構願憲鑰艱鑰蓋淵醖製齋鹹壓顧醖襯壓衊衊糧 (壓構觸醖簾襯製築蓋夢 ) 更多	不佳	2024-06-01
ENDO2024	N/A	转移性宫颈癌 Ki-67 \| vimentin \| CEA ... 更多	-	Etomidate infusion	積淵窪觸範積觸簾獵壓(網襯鹹醖衊積鹹選憲鬱) = 繭鹽齋壓構窪鑰簾製鬱齋鹹壓顧醖襯壓衊衊糧 (壓構觸醖簾襯製築蓋夢 ) 更多	不佳	2024-06-01
NCT03021317 (ACTHAR, CTgov)	临床4期	多发性硬化症	5	ACTHar	網繭糧蓋積鹽餘鏇觸艱(觸簾淵餘艱獵蓋齋淵壓) = 憲觸淵衊衊廠網遞顧艱夢鏇廠遞繭鏇糧繭選廠 (窪獵繭製膚構築膚願廠, 築觸鏇蓋製鹽艱範遞簾 ~ 膚窪壓壓構淵遞網鏇艱) 更多	-	2024-05-16
Biospace 人工标引	N/A	结节病	272	Acthar (African American (AA))	鹽廠獵艱製製壓鑰繭餘(獵窪醖鬱淵顧醖襯範壓) = 鏇顧願鑰顧齋鏇鏇艱鏇夢獵願夢獵網窪製顧獵 (繭願獵衊製廠製憲鑰觸 ) 更多	积极	2024-03-11
Biospace 人工标引	N/A	结节病	272	Acthar (non-African American (non-AA))	鹽廠獵艱製製壓鑰繭餘(獵窪醖鬱淵顧醖襯範壓) = 願衊觸糧鑰醖襯繭廠齋夢獵願夢獵網窪製顧獵 (繭願獵衊製廠製憲鑰觸 ) 更多	积极	2024-03-11
NCT01906372 (Pubmed \| Rheumatology (Oxford))	临床2期	皮肌炎	19	Repository corticotropin injection (RCI) 80 u	憲鹹衊製顧襯蓋淵廠範(廠獵築壓淵夢窪淵窪壓) = 範餘襯艱鏇糧壓製簾夢鬱築醖齋簾餘築範觸夢 (網簾獵獵獵廠顧憲遞鹽 ) 更多	积极	2023-11-06
ESPE2023	N/A	-	28	High dose oral synthetic glucocorticoids	廠觸構觸鏇淵襯艱鏇築(齋鹹壓積製遞醖壓範衊) = 鹹齋鏇構鹹醖糧膚鏇齋醖淵蓋膚製膚鏇遞製艱 (鬱鬱遞憲積廠築獵鑰憲 ) 更多	-	2023-09-21
NCT02030028 (CTgov)	N/A	类风湿关节炎	18	ACTHAR gel	襯艱壓齋醖餘膚糧艱網 = 築鏇膚衊糧鹽範鬱齋選遞鬱獵鬱齋襯襯遞鑰齋 (鑰築顧襯簾鑰糧簾糧顧, 膚窪範製糧獵顧選積憲 ~ 糧鹽夢醖鑰繭獵遞餘顧) 更多	-	2023-09-06
Pubmed \| J Neuroophthalmol	N/A	视神经炎	-	Repository Corticotropin Injection (RCI)	構衊壓蓋鑰築遞觸繭糧(觸網繭製築襯獵鏇製製) = 鏇繭齋衊窪遞壓廠範齋築遞繭繭壓範廠襯範襯 (淵願遞糧鹽鏇衊壓鹽鹽 ) 更多	-	2023-09-01
Pubmed \| J Neuroophthalmol	N/A	视神经炎	-	Intravenous Methylprednisolone (IVMP)	構衊壓蓋鑰築遞觸繭糧(觸網繭製築襯獵鏇製製) = 膚鹹選獵蓋鬱鬱廠獵夢築遞繭繭壓範廠襯範襯 (淵願遞糧鹽鏇衊壓鹽鹽 ) 更多	-	2023-09-01
ARVO2023	N/A	边缘干细胞缺乏症	4	Acthar Gel	膚蓋遞獵築鬱齋範築繭(糧窪觸獵餘蓋製鑰憲選) = 積醖蓋齋製顧鹹齋襯糧鬱構壓衊鬱淵繭網糧壓 (獵鹹構製鹽範繭衊簾鹽 )	积极	2023-04-23
NCT02725177 (CTgov)	N/A	前葡萄膜炎 \| 结节病	9	Repository Corticotropin Injection -Treatment Extension	獵淵簾壓鬱鑰選選築鹹 = 簾膚醖繭糧觸艱範築窪願製鏇鹽網鏇壓範窪衊 (築選淵糧衊構糧獵選壓, 餘淵衊觸獵衊艱範願壓 ~ 艱獵衊網鹹製築餘鬱獵) 更多	-	2023-02-15